Litcius/Paper detail

Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial

Vivek Shinde, Iksung Cho, Joyce S Plested, Sapeckshita Agrawal, Jamie Fiske, Rongman Cai, Haixia Zhou, Xuan Pham, Mingzhu Zhu, Shane Cloney-Clark, Nan Wang, Bin Zhou, Maggie Lewis, Patty Price-Abbott, Nita Patel, Michael J Massare, Gale Smith, Cheryl Keech, Louis Fries, Gregory M Glenn

2021The Lancet Infectious Diseases69 citationsDOI

Topics & Concepts

MedicineImmunogenicitySeasonal influenzaRandomized controlled trialInfluenza vaccineVirologyLive attenuated influenza vaccineVaccinationImmunologyAntibody responseVaccine trialInternal medicineClinical trialVaccine efficacySeroconversionImmunizationInfluenza A virusTrivalent influenza vaccineImmune systemPhase (matter)OrthomyxoviridaeInfluenza Virus Research StudiesImmunotherapy and Immune ResponsesInfection Control and Ventilation
Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial | Litcius